Cargando…
Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
BACKGROUND: Globally, drug resistant tuberculosis (DR-TB) continues to be a public health threat. Nigeria, which accounts for a significant proportion of the global burden of rifampicin/multi-drug resistant-TB (RR/MDR-TB) had a funding gap of $168 million dollars for TB treatment in 2018. Since 2010...
Autores principales: | Bada, Florence O., Blok, Nick, Okpokoro, Evaezi, Dutt, Saswata, Akolo, Christopher, Dakum, Patrick, Abimiku, Alash’le |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707487/ https://www.ncbi.nlm.nih.gov/pubmed/33259492 http://dx.doi.org/10.1371/journal.pone.0241065 |
Ejemplares similares
-
Correction: Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria
por: Bada, Florence O., et al.
Publicado: (2021) -
Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
por: Bada, Florence O., et al.
Publicado: (2019) -
Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria
por: Osawe, Sophia, et al.
Publicado: (2016) -
Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020) -
Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
por: Anude, Chuka J, et al.
Publicado: (2013)